Early use of probiotics is important therapy in infants with severe congenital anomaly

Yutaka Kanamori1, Tadashi Iwanaka, Masahiko Sugiyama

  • 1Department of Pediatric Surgery, University of Tokyo Hospital, Bunkyo-ku, Japan. kanamori-psu@h.u-tokyo.ac.jp

Insights

Probiotic therapy effectively restored normal gut bacteria in infants with severe congenital anomalies, preventing infections and promoting excellent physical growth despite complex health challenges.

Area of Science:

  • Neonatal surgery
  • Microbiome research
  • Pediatric gastroenterology

Background:

  • Infants with severe congenital anomalies often develop abnormal gut microbiota post-surgery and antibiotic treatment.
  • This dysbiosis can lead to severe infections like necrotizing enterocolitis, impaired intestinal function, and poor nutritional status.

Purpose of the Study:

  • To evaluate the efficacy of probiotic therapy as a supportive treatment for infants with severe congenital anomalies.
  • To investigate the impact of probiotics on intestinal microbiota and physical growth in this vulnerable population.

Main Methods:

  • Four infants with severe congenital anomalies received probiotic therapy with Bifidobacterium breve Yakult and Lactobacillus casei Shirota post-surgery.
  • Intestinal microbiota composition and physical growth parameters were monitored throughout the treatment period.

Main Results:

  • Probiotic therapy successfully shifted the intestinal microbiota from a dysbiotic state to a probiotic-dominant and then a commensal anaerobe-dominant profile, resembling normal microbiota.
  • Pathogenic bacteria were rarely detected.
  • Patients exhibited excellent physical growth, even with conditions like short bowel and pulmonary hypoplasia.

Conclusions:

  • Probiotic therapy is effective in normalizing intestinal microbiota in infants with severe congenital anomalies.
  • This normalization activated intestinal absorptive functions, completely preventing severe infections.
  • All treated infants demonstrated positive physical development despite significant congenital disadvantages.
Abstract

Related Concept Videos

Microbiota Modulation by Antibiotics01:21

Microbiota Modulation by Antibiotics

Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...
Probiotics01:22

Probiotics

Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...
Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Anatomy of the Intestines01:23

Anatomy of the Intestines

Although digestion of proteins, carbohydrates, and lipids may begin in the stomach, it is completed in the intestine. The absorption of nutrients, water, and electrolytes from food and drink also occurs in the intestine. The intestines can be divided into two structurally distinct organs—the small and large intestines.
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the small...